Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Rigel Pharmaceutical Inc. diskutieren

Rigel Pharmaceutical Inc.

WKN: 766093 / Symbol: RIGL / Name: Rigel Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,86 €
-0,90 %

Einschätzung Buy
Rendite (%) -26,50 %
Kursziel 13,71
Veränderung
Endet am 02.08.24

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for RIGL provided by MarketBeat

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for RIGL provided by MarketBeat

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for RIGL provided by MarketBeat

Einschätzung Buy
Rendite (%) -25,22 %
Kursziel 13,91
Veränderung
Endet am 08.12.24

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for RIGL provided by MarketBeat

Einschätzung Buy
Rendite (%) -37,04 %
Kursziel 13,69
Veränderung
Endet am 04.01.25

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for RIGL provided by MarketBeat

Einschätzung Buy
Rendite (%) -30,36 %
Kursziel 13,86
Veränderung
Endet am 22.02.25

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for RIGL provided by MarketBeat

Einschätzung Buy
Rendite (%) -38,83 %
Kursziel 13,77
Veränderung
Endet am 06.03.25

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for RIGL provided by MarketBeat

Einschätzung Buy
Rendite (%) -38,68 %
Kursziel 3,67
Veränderung
Endet am 07.03.25

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $3.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for RIGL provided by MarketBeat

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for RIGL provided by MarketBeat

Einschätzung Buy
Rendite (%) -11,66 %
Kursziel 13,95
Veränderung
Endet am 08.05.25

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for RIGL provided by MarketBeat